Viking Therapeutics Takeover Target in Biotech Investing?
Investors increasingly ask whether Viking Therapeutics could become a takeover target. This article breaks down why b...
When To Switch From Target Date Fund To Age Based Approach: Go. This intro covers when a switch makes sense and what signals to watch for in your plan.
25,368 articlesInvestors increasingly ask whether Viking Therapeutics could become a takeover target. This article breaks down why b...
Goldman Sachs and KeyBanc boosted AT&T price targets after the telecom giant unveiled a three-segment reporting model...
A Sunrun director recently disposed of a large block of shares. This article breaks down insider sales, what they imp...
A Nurix Therapeutics insider recently sold shares, drawing attention from investors. This article breaks down the mov...
A major fund recently shed about $20 million worth of Graphic Packaging shares, prompting questions about the company...
Franklin Templeton has filed for two ETFs that reinvest stock dividends into Bitcoin, with an expected launch as earl...
Want higher dividends from international stocks? This guide explains how VYMI works, who it helps, and how to use it ...
Palantir has cooled off after a blazing run, but analysts say there's still meaningful upside. This guide breaks down...
A recent SEC filing shows Pale Fire Capital expanding its Ziff Davis position. This move offers clues about hedge fun...
Many workers find themselves taking on tasks they didn’t apply for, often with no raise or promotion in sight. This a...
When market turbulence rises, even growth-focused firms recalibrate. Francis Financial doubles down on fixed income, ...
JPMorgan raises its IREN price target to $46 but preserves an underweight stance, citing structural risk in NVIDIA’s ...